Takara Bio Inc TKBIF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- 400 / 400
Key Statistics
- Price/Earnings (Normalized)
- 16.81
- Price/Sales
- 4.93
- Dividend Yield (Trailing)
- 1.05%
- Dividend Yield (Forward)
- 1.05%
- Total Yield
- 1.05%
Company Profile
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,793
- Website
- http://www.takara-bio.co.jp
Comparables
Valuation
|
Metric
|
TKBIF
|
4563
|
4587
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.81 | — | 54.03 |
Price/Book Value | 3.60 | 0.38 | 6.32 |
Price/Sales | 4.93 | 36.38 | 9.05 |
Price/Cash Flow | 12.88 | — | 111.21 |
Price/Earnings
TKBIF
4563
4587
Financial Strength
|
Metric
|
TKBIF
|
4563
|
4587
|
|---|---|---|---|
Quick Ratio | 5.27 | 0.85 | 3.18 |
Current Ratio | 7.45 | 1.63 | 3.50 |
Interest Coverage | 52.29 | — | 2.50 |
Quick Ratio
TKBIF
4563
4587
Profitability
|
Metric
|
TKBIF
|
4563
|
4587
|
|---|---|---|---|
Return on Assets (Normalized) | 1.43% | −12.91% | 3.58% |
Return on Equity (Normalized) | 1.60% | −15.67% | 6.40% |
Return on Invested Capital (Normalized) | 1.49% | −15.23% | 6.31% |
Return on Assets
TKBIF
4563
4587
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nzgxjzmsx | Npck | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fxkjhfz | Dtbtclm | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mkkrgtxg | Kzrmyr | $107.8 Bil | |
MRNA
| Moderna Inc | Zrpbxvqb | Kljz | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Kwslrmbw | Mlslm | $22.2 Bil | |
ARGX
| argenx SE ADR | Gjfcphqqh | Fngfw | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nffpbfzg | Gsxjrx | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vqncplph | Bsjskh | $15.1 Bil | |
INCY
| Incyte Corp | Ktpmrhjy | Hqtxgln | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mhytyknrvd | Cfgzl | $12.7 Bil |